CN101897949B - Low irritant transparent emulsion dosage form is for the medical composite for eye of eyes or the surface immunomodulating of around eyes related organization and antiinflammatory - Google Patents
Low irritant transparent emulsion dosage form is for the medical composite for eye of eyes or the surface immunomodulating of around eyes related organization and antiinflammatory Download PDFInfo
- Publication number
- CN101897949B CN101897949B CN201010119881.0A CN201010119881A CN101897949B CN 101897949 B CN101897949 B CN 101897949B CN 201010119881 A CN201010119881 A CN 201010119881A CN 101897949 B CN101897949 B CN 101897949B
- Authority
- CN
- China
- Prior art keywords
- eye
- ciclosporin
- medical composite
- percentage
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention provides a kind of low irritant transparent emulsion dosage form medical composite for eye for eyes or the surface immunomodulating of around eyes related organization and antiinflammatory, for treating serious keratoconjunctivitis sicca the inflammatory response of conjunctival epithelium pathological changes patient, it is formed as emulsion dosage form and comprises the castor oil derivatives such as at least one ciclosporin, propylene glycol and such as CREMOPHORE EL, and transparent shape there is low irritant, the stable and feature of nodeless mesh phenomenon, it is applicable to the more sensitive areas such as eye tissue.
Description
Technical field
The present invention relates to a kind of medical composite for eye, especially relate to a kind of low irritant transparent emulsion dosage form that is formed as supply eyes or the medical composite for eye about the surface immunity adjustment of organ or tissue and antiinflammatory.
Background technology
Ciclosporin group is the nonpolar circulation oligopeptide (oligopeptides) that a group has immunosuppressive activity, and ciclosporin A (cyclosporineA) and other several be identified as the ciclosporin B (cyclosporineB) of small metabolism thing, ciclosporin C (cyclosporineC), Ciclosporin D (cyclosporineD), ciclosporin E (cyclosporineE) to such an extent as to ciclosporin H (cyclosporineH) comes under ring spore group.These ciclosporins group is made up of 11 kinds of peptides.A kind of application ciclosporin effectively processes the technology of immunity keratoconjunctivitis sicca (keratoconjunctivitissicca, KCS, or claim xerophthalmia) disclosed in No. 4839342 United States Patent (USP) (U.S.Pat.No.4,839,342).
Ciclosporin possesses immunoinhibitory and can improve or recover ocular fluid produced by lachrymal gland.But, owing to ciclosporin water-soluble is very low, U.S. Patent No. 5051402 (U.S.Pat.No.5,051,402) is thought can not make ciclosporin aqueous solution by ciclosporin.Although polyoxyethylene castor oil can be utilized when avoiding ciclosporin to precipitate to make injection as cosolvent, but the safety problem of being likely to result in.Additionally, be related to not adopt polyoxyethylene castor oil as cosolvent, and use cyclodextrin (cyclodextrins) instead as working as cosolvent, with make ciclosporin aqueous solution technology also for disclosed by prior art.
In connection with the usual knowledge of ciclosporin, when aforementioned ciclosporin water-soluble liquid cosolvent suffers the liquid dilutings such as the body fluid of organism, reduction solubilization-aid effect is caused, and ciclosporin can not dissolve well and precipitate.Namely when manufacturing containing the pharmaceutical composition of ciclosporin, it is necessary to manage to overcome body fluid dilution cause ciclosporin can not the problem of excellent dissolution, the shortcoming being produced deposited phenomenon after being diluted by the water in body fluid during to avoid this pharmaceutical composition thereof body fluid containing ciclosporin.
The medicament excipient being directly used in the existing eye cyclosporin pharmaceutical composition such as such as eye cyclosporin pharmaceutically dosage form includes animal oil, vegetable oil, organic solution, aqueous solution, artificial tears, natural polymer, synthetic polymer or is suitable for ophthalmically acceptable thin film.General single medicament or confection allow that the excipient of employing then includes olive oil, Oleum Arachidis hypogaeae semen, castor oil, mineral oil, vaseline, dimethyl sulfoxide, polyoxyethylene castor oil derivant (polyethylenecastoroilderivatives), liposome or silicone.
No. 5474979 United States Patent (USP) (U.S.Pat.No.5,474,979) disclosed in, one has and applies more high fatty acid glyceride (higherfattyacidglyceride) and the Tween 80 (Tween80) as emulsifying Yu dispersant such as such as castor oil (castoroil), has low irritant to make and sufferer can be allowed to feel the technology of comfortable ciclosporin emulsion dosage form medical composite for eye.But, the emulsion made by water-fast castor oil and glycerol (glycerin) is utilized owing to this existing ciclosporin emulsion dosage form medical composite for eye is made for one, its droplet diameter is more than 0.2 micron (0.2 μm, i.e. 200 nanometers (nm)), hence in so that ciclosporin not easily absorbs and drug effect is slow, also lead to ciclosporin not easily mix with ocular fluid simultaneously, and probably due to the castor oil as cosolvent is diluted by ocular fluid and makes the ciclosporin generation deposited phenomenon as main constituent.
Additionally, No. 5474979 emulsion dosage form medical composite for eye disclosed in U.S. Patent adopts such as carbomer (carbomer) etc. to have irritating composition for eye mucosa, it is unfavorable for manufacturing medical composite for eye." high-quality skin care products selection strategy " (Zhang Liqing, connection through publishing house, on July 10th, 2003) then describes about the carbomer explanation for eye irritation on mucous membrane.
Again, adopt castor oil the existing emulsion dosage form medical composite for eye by carbomer increase denseness disclosed in No. 5474979 United States Patent (USP) are creamy white.Therefore this existing emulsion dosage form medical composite for eye maintains milky white and opaque state when being applied, it would be possible to cause the problem hindering the visual field to be unfavorable for being applied to eye.
Summary of the invention
Because the shortcoming of above-mentioned existing medical composite for eye, it is an object of the invention to provide a kind of medical composite for eye being suitable for eye and there is transparent microemulsified liquid characteristic.
For reaching above-mentioned purpose, the technological means that the present invention takes is the low irritant transparent emulsion making this medical composite for eye be formed as being suitable for eye tissue, comprising:
Ciclosporin, described ciclosporin includes ciclosporin A；
Tonicity regulator, described tonicity regulator selects the group that free propylene glycol, glycerol, mannitol and Sorbitol form；
Polyoxyl35 castor oil；And
Pure water.
Owing to this tonicity regulator has, dissolubility is good, zest is low, and the transparent shape of polyoxyl35 castor oil, zest are low, its oil droplet is small and possesses microemulsion characteristic, therefore the medical composite for eye of the present invention has the advantage that, does not hinder the visual field be particularly suitable for eye and have microemulsion characteristic.
Aspect and advantage that the present invention adds will part provide in the following description, and part will become apparent from the description below, or is recognized by the practice of the present invention.
Detailed description of the invention
Being described below in detail embodiments of the present invention, embodiments described below is illustrative of, and is only used for explaining the present invention, and is not construed as limiting the claims.
The present invention is a kind of new medical composite for eye, and it relates to such as ciclosporin etc. and not readily dissolves the compound in water.The medical composite for eye of the present invention is be formed as the ciclosporin emulsion containing propylene glycol (propyleneglycol) and polyoxyethylene castor oil derivant, and it can provide the sensation of high comfort, and zest is low.
The medical composite for eye of the present invention is ophthalmically acceptable emulsion dosage form, its low irritant transparent emulsion being formed as being prone to input sensitive visual region, and its component includes ciclosporin, propylene glycol, polyoxyalkylene 35 castor oil, polyvinyl alcohol and pure water.
Described ciclosporin is a kind of mixture, and it includes at least one oligopeptide belonging to ciclosporin group.This at least one oligopeptide belonging to ciclosporin group mainly includes ciclosporin A, it is possible to farther include one or more oligopeptide selected from ciclosporin B～E, H.When implementing the present invention, it is possible to make the ciclosporin of medical composite for eye composition of the present invention only include ciclosporin A, it is possible to so that it includes ciclosporin A and one or more are selected from the oligopeptide of ciclosporin B～E, H.
Described tonicity regulator is in order to adjust osmotic pressure, namely medicament for the eyes agent tonicity (tonicity), so that the medical composite for eye of the present invention can reach suitable osmotic pressure when being applied to ill eye, make to suffer from patient and feel comfortably cool without producing sense of discomfort due to the osmotic pressure of eyes and medical composite for eye difference.The medical composite for eye of the present invention can adopt such as propylene glycol, glycerol, mannitol (mannitol) or Sorbitol (sorbitol) etc. as described tonicity regulator.Wherein, propylene glycol is used as preservative (preservative), cosolvent (co-solvent), Humectant (humectant), reinforcing agent (enhancer), stabilizer (Stabilizer) and solvent, and can increase permeability thus being able to the composition as the osmotic pressure adjusting medicament for the eyes.Propylene glycol has the dissolubility being better than glycerol, though its zest is slightly stronger than glycerol, but the zest of propylene glycol still extremely slightly (refers to HandbookofPharmaceuticalExcipients, ThirdEdition, PublishedbytheAmericanPharmaceuticalAssociation (2000), Pages442-444).Owing to the consumption of propylene glycol in the present invention is extremely low, therefore with regard to physiology impression upper for, medical composite for eye provided by the present invention can be allowed when adopting propylene glycol as tonicity regulator to maintain low irritant and to be beneficial to be applied to eye.
The castor oil that the medical composite for eye of prior art adopts is lipophile and water-immiscible, but polyoxyl35 castor oil of the present invention (polyoxyl35castoroil) belongs to hydrophilic and tends to the polyoxyethylene castor oil derivant miscible with water, it can as non-ionic surfactant, thus being mainly applied to emulsifying and lytic agent, it is particularly suitable for manufacturing the aqueous solution of lipophilicity substance.Owing to ciclosporin is lipophilicity substance, the polyoxyethylene castor oil derivants such as such as polyoxyl35 castor oil therefore can be adopted to prepare ciclosporin aqueous solution as interfacial agent.Simultaneously, the polyoxyethylene castor oil derivants such as such as polyoxyl35 castor oil are low irritant and avirulence (refers to HandbookofPharmaceuticalExcipients, ThirdEdition, PublishedbytheAmericanPharmaceuticalAssociation (2000), Pages412-415), therefore it is suitable for manufacturing medical composite for eye.
In addition, although polyoxyalkylene 35 castor oil and castor oil all belong to low irritant, but castor oil is oiliness, it is easily detected by 0.2 micron membrane filter with emulsion made by castor oil, and polyoxyl35 castor oil is hydrophilic, 0.2 micron membrane filter can be passed through with the oil droplet of transparent emulsion made by polyoxyl35 castor oil.In other words, excessively thick with the oil droplet of the emulsion made by castor oil, it is not belonging to microemulsion (microemulsion)；But with the droplet diameter of the emulsion made by polyoxyalkylene 35 castor oil less than 0.2 micron, belong to microemulsion, thus being easier to absorb, drug effect is very fast.
Owing to the medical composite for eye of the present invention is the emulsion being formed as having described microemulsion characteristic, therefore the medical composite for eye of the present invention can be directly over 0.2 micron filter advantageously to remove the cause of diseases such as antibacterial.Otherwise, existing medical composite for eye is form is the emulsion made with castor oil and glycerol, does not have microemulsion character, it is impossible to directly use 0.2 micron membrane filter to filter cause of disease.Therefore the more existing medical composite for eye of the manufacturing speed of the medical composite for eye of the present invention is quick, and easier owing to can pass through 0.2 micron membrane filter employing degerming processing procedure, thus being conserved manufacturing cost.
The medical composite for eye of the present invention is utilize to be dissolved in the polyoxyl35 castor oil of water and propylene glycol is formed as emulsion dosage form, therefore it easily mixes with ocular fluid and does not make to precipitate as the ciclosporin of main constituent, can improve existing medical composite for eye adopts the emulsion that the castor oil not easily mixed with ocular fluid and glycerol are made to cause the shortcoming easily precipitated as the ciclosporin of main constituent, it is known that the shortcoming that the medical composite for eye of the present invention can improve this medical composite for eye existing.
Owing to using appropriate pure water to belong to known technology as the technology of its composition when manufacturing the pharmaceutical composition of emulsion dosage form, therefore omit and it will not go into details.
Additionally, the medical composite for eye of the present invention can adopt the such as packaging material such as ampuliform or capsule shape container to pack in units of single dose or multiple dose.Wherein, when the medical composite for eye of the present invention is packed in units of single dose, use up in real time after being opened due to each packing unit, therefore without outer adding preservative agent.But, when the medical composite for eye of the present invention is packed in units of multiple dose, it is likely to after being opened due to each packing unit need just to use up through long-time repeatedly use, therefore can add preservative separately.
Preservative is allowed to be applied to medical composite for eye after being based on the examination & verification of the specific responsibility units such as such as FDA.Such as benzalkonium chloride (benzalkoniumchloride), benzyl alcohol (benzylalcohol), Benzene Chloride the first and second oxygen ammonium (benzethoniumchloride), methaform (chlorobutanol), chlorocresol (chlorocresol), methyl parahydroxybenzoate (Methylyparaben), benzoglycols (Phenylethylalcohol) or what merthiolate (thimerosal) belonged to.
Again, for increasing medical composite for eye denseness, enable the medical composite for eye of emulsion dosage form to keep the long period and not easily landing at eye, thickening agent can be added separately to reach thickening effect.
Thickening agent is also after the examination & verification according to the specific responsibility unit such as such as FDA, the person that is allowed to be applied to medical composite for eye.Such as carbomer, polyvinyl alcohol (polyvinylalcohol), hydroxyl second two cellulose (hydroxyethylcellulose) or methylcellulose (methylcellulose) etc..
At such as U.S.Pat.No.5,474, the medical composite for eye provided in prior art illustrated in 979 is only with castor oil and as the carbomer of thickening agent, and the medical composite for eye of the present invention adopts polyoxyethylene castor oil derivant and using compositions such as polyvinyl alcohol as thickening agent, there is the effect being better than prior art, good hydrophilic can be played to avoid ciclosporin to precipitate, and the zest to eyes can be reduced.
It addition, the emulsion adopting castor oil and carbomer that prior art provides is creamy white and is not suitable for medicament for the eyes, but the emulsifying agent of the present invention is transparent, colourless；The droplet diameter of its emulsifying increases denseness less than 0.2 micron with polyvinyl alcohol, enables the medical composite for eye being formed as emulsion dosage form to keep the long period and not easily landing at eye, does not also hinder the visual field, and be provided to patient's more comfortable feel.
Again, for adjusting the pH value (also known as " hydrogen ion exponent ") of medical composite for eye provided by the present invention, sodium hydroxide can be adopted to be adjusted to the acceptable pH value of applicable medicament for the eyes.
Illustrated in the concrete recipe quantity of the medical composite for eye of the present invention such as table 1.Moreover the medical composite for eye of the present invention is adopted the composition combination of such as ciclosporin A, propylene glycol, polyoxyl35 castor oil, polyvinyl alcohol, benzalkonium chloride and water that ciclosporin A generation crystalloid can be avoided to be applicable to eye tissue.
Table 1
From described above and illustrated concrete recipe quantity:
(1) medical composite for eye of the present invention is be formed as being directly over 0.2 micron filter to remove the emulsion dosage form of antibacterial, can save manufacturing time thus being minimized cost.
(2) medical composite for eye of the present invention be formed as transparent emulsion dosage form, the visual field will not be hindered during use.
(3) the medical composite for eye zest of the present invention is low, is therefore suitable for being applied to eye.
(4) medical composite for eye of the present invention be formed as emulsion dosage form and its oil droplet less than 0.2 micron, there is the characteristic being prone to microemulsions such as absorbing, drug effect is quick.
From the above, the medical composite for eye of the present invention is be formed as the emulsion dosage form with characteristics such as transparent, low irritants containing ciclosporin, can provide to treat the eye medicinal of the inflammatory response of the patient of serious keratoconjunctivitis sicca conjunctival epithelium pathological changes, to improve the shortcoming of existing medical composite for eye, thus reaching the purpose of the present invention.
Although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, being appreciated that and these embodiments can be carried out multiple change, amendment, replacement and modification without departing from the principles and spirit of the present invention, the scope of the present invention be defined by the appended.
Claims (8)
1. a medical composite for eye, its low irritant transparent emulsion being formed as being suitable for eye tissue, comprising:
Ciclosporin, described ciclosporin includes ciclosporin A, described in encircle the content of element to account for the percentage by weight of described medical composite for eye be 0.01-0.40%；
Tonicity regulator, described tonicity regulator is propylene glycol, and it is 0.1-3.0% that the content of described propylene glycol accounts for the percentage by weight of described medical composite for eye；
Polyoxyl35 castor oil, it is 0.1-6.0% that the content of described CREMOPHORE EL accounts for the percentage by weight of described medical composite for eye；And
Pure water；
Described medical composite for eye has the oil droplet of emulsifying, and the droplet diameter of described emulsifying is less than 0.2 micron.
2. medical composite for eye as claimed in claim 1, it farther includes:
Preservative, described preservative selects the group that free benzalkonium chloride, benzyl alcohol, Benzene Chloride the first and second oxygen ammonium, methaform, chlorocresol, methyl parahydroxybenzoate, benzoglycols and merthiolate form；
Thickening agent, described thickening agent selects the group that free polyvinyl alcohol, hydroxyl second two cellulose or methylcellulose form.
3. medical composite for eye as claimed in claim 2, described tonicity regulator is propylene glycol；
Described preservative is benzalkonium chloride；
Described thickening agent is polyvinyl alcohol.
4. medical composite for eye as claimed in claim 3, it is 0.05-0.40% that the content of described ciclosporin accounts for the percentage by weight of medical composite for eye；
It is 0.1-3.0% that the content of described propylene glycol accounts for the percentage by weight of medical composite for eye；
It is 0.1-6.0% that the content of described polyoxyl35 castor oil accounts for the percentage by weight of medical composite for eye；
It is 0.1-6.0% that the content of described polyvinyl alcohol accounts for the percentage by weight of medical composite for eye；
It is 0.01-0.02% that the content of described benzalkonium chloride accounts for the percentage by weight of medical composite for eye.
5. the medical composite for eye as according to any one of Claims 1-4 item, described ciclosporin farther includes the oligopeptide of one or more groups selecting free ciclosporin B, ciclosporin C, Ciclosporin D, ciclosporin E and ciclosporin H to form.
6. the medical composite for eye as according to any one of Claims 1-4, it is in order to treat keratoconjunctivitis sicca, and is packed in units of single dose by packaging material.
7. medical composite for eye as claimed in claim 6, described ciclosporin farther includes the oligopeptide of one or more groups selecting free ciclosporin B, ciclosporin C, Ciclosporin D, ciclosporin E and ciclosporin H to form.
8. the medical composite for eye as described in any one of claim 2 to 4, it is in order to treat keratoconjunctivitis sicca, and is packed in units of multiple dose by packaging material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010119881.0A CN101897949B (en) | 2010-02-24 | 2010-02-24 | Low irritant transparent emulsion dosage form is for the medical composite for eye of eyes or the surface immunomodulating of around eyes related organization and antiinflammatory |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010119881.0A CN101897949B (en) | 2010-02-24 | 2010-02-24 | Low irritant transparent emulsion dosage form is for the medical composite for eye of eyes or the surface immunomodulating of around eyes related organization and antiinflammatory |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101897949A CN101897949A (en) | 2010-12-01 |
| CN101897949B true CN101897949B (en) | 2016-07-06 |
Family
ID=43224089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010119881.0A Active CN101897949B (en) | 2010-02-24 | 2010-02-24 | Low irritant transparent emulsion dosage form is for the medical composite for eye of eyes or the surface immunomodulating of around eyes related organization and antiinflammatory |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101897949B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108066745A (en) * | 2017-12-26 | 2018-05-25 | 兆科药业（广州）有限公司 | A kind for the treatment of process of Ciclosporin eye gel |
| CN115463088A (en) * | 2021-06-11 | 2022-12-13 | 温士顿医药股份有限公司 | Ophthalmic nanoemulsion composition containing prostaglandin derivative |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1250377A (en) * | 1997-03-12 | 2000-04-12 | 艾博特公司 | Hydrophilic binary systems for the administration of cyclosporine |
| CN1288722A (en) * | 1994-05-17 | 2001-03-28 | 阿勒根销售公司 | Tear-gland specific emulsion for local application to eye tissue |
| CN1463746A (en) * | 2002-06-18 | 2003-12-31 | 福建科瑞药业有限公司 | Micro-emulsified pre-concentration oral solution containing Ciclosporin A |
| CN1686533A (en) * | 2005-03-25 | 2005-10-26 | 中国科学院上海药物研究所 | Cyclosporia A microemulsion for eye and its preparation method |
| TW201127393A (en) * | 2010-02-04 | 2011-08-16 | Winston Medical Supply Co Ltd | Ophthalmic pharmaceutical composition in the dosage form of a low-irritating and translucent emulsion for the treatment of topical immunomodulator with anti-inflammatory effect of the eye or the surrounding or associated tissues thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7588786B2 (en) * | 2001-11-14 | 2009-09-15 | Jarrow Formulas, Inc. | Eutectic-based self-nanoemulsified drug delivery system |
-
2010
- 2010-02-24 CN CN201010119881.0A patent/CN101897949B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1288722A (en) * | 1994-05-17 | 2001-03-28 | 阿勒根销售公司 | Tear-gland specific emulsion for local application to eye tissue |
| CN1250377A (en) * | 1997-03-12 | 2000-04-12 | 艾博特公司 | Hydrophilic binary systems for the administration of cyclosporine |
| CN1463746A (en) * | 2002-06-18 | 2003-12-31 | 福建科瑞药业有限公司 | Micro-emulsified pre-concentration oral solution containing Ciclosporin A |
| CN1686533A (en) * | 2005-03-25 | 2005-10-26 | 中国科学院上海药物研究所 | Cyclosporia A microemulsion for eye and its preparation method |
| TW201127393A (en) * | 2010-02-04 | 2011-08-16 | Winston Medical Supply Co Ltd | Ophthalmic pharmaceutical composition in the dosage form of a low-irritating and translucent emulsion for the treatment of topical immunomodulator with anti-inflammatory effect of the eye or the surrounding or associated tissues thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101897949A (en) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004321183B2 (en) | Oleaginous pharmaceutical and cosmetic foam | |
| JP5441058B2 (en) | Composition comprising a quaternary ammonium compound | |
| RU2651046C2 (en) | Dry eye treatment compositions | |
| CN100478025C (en) | Cyclosporia A microemulsion for eye and its preparation method | |
| EP2726060B1 (en) | Macrogol 15 hydroxystearate formulations | |
| CN101340884A (en) | Methods for the treatment of hyperhidrosis | |
| US10039803B2 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
| JP6962663B2 (en) | Ophthalmic composition and its manufacturing method | |
| CA2810267A1 (en) | Combination of compounds for treating or preventing skin diseases | |
| JP2002097129A (en) | Eye lotion | |
| CN105726479B (en) | cyclosporine ophthalmic emulsion | |
| CN101897949B (en) | Low irritant transparent emulsion dosage form is for the medical composite for eye of eyes or the surface immunomodulating of around eyes related organization and antiinflammatory | |
| CN113577024A (en) | Ophthalmic composition and preparation method and application thereof | |
| CA3149270A1 (en) | Nanoemulsion ophthalmic composition comprising cyclosporine and menthol, and preparation method thereof | |
| JP4718160B2 (en) | Ophthalmic composition | |
| KR20080053319A (en) | Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis | |
| CN100562340C (en) | A kind of micro-emulsion type artificial tear | |
| JP2013256462A (en) | Water-based composition including vitamin a group | |
| KR20160096376A (en) | Ophthalmic composition comprising hyaluronic acid, mineral oil and surfactants | |
| KR20190071674A (en) | Ophthalmic preparations and ophthalmic preparations | |
| WO2004112789A1 (en) | Ophthalmic composition | |
| ES2850366T3 (en) | Composition for the treatment of blepharitis containing terpinen-4-ol | |
| KR20210088623A (en) | artificial tears | |
| TW201127393A (en) | Ophthalmic pharmaceutical composition in the dosage form of a low-irritating and translucent emulsion for the treatment of topical immunomodulator with anti-inflammatory effect of the eye or the surrounding or associated tissues thereof | |
| JP5627235B2 (en) | Ophthalmic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200514 Address after: No. 40, Xiwu District, No. 888, Puhe Avenue, shenbeixin District, Shenyang City, Liaoning Province Patentee after: Al health eye medicine (Liaoning) Co., Ltd Address before: Tainan County, Taiwan, China Patentee before: WINSTON MEDICAL SUPPLY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 110136 No.40, West No.5 District, 888 Puhe Avenue, Shenbei New District, Shenyang City, Liaoning Province Patentee after: Al health medicine (Liaoning) Co.,Ltd. Address before: 110136 No.40, West No.5 District, 888 Puhe Avenue, Shenbei New District, Shenyang City, Liaoning Province Patentee before: Al health eye medicine (Liaoning) Co.,Ltd. |